Please check your internet connection and try again.
# Dexamethasone in Chronic Immune Thrombocytopenia (ITP)
## Overview
Dexamethasone is a potent, long-acting synthetic glucocorticoid with minimal mineralocorticoid activity. In refractory or chronic ITP, high-dose pulses are used to induce rapid, transient increases in platelet counts by suppressing macrophage-mediated platelet destruction and inhibiting autoantibody production.
## Primary Indications
Second-line therapy for chronic ITP; also utilized in acute settings to achieve rapid platelet recovery (e.g., prior to procedures).
## Adult Dosing
* **High-Dose Pulse:** 40 mg orally once daily for 4 consecutive days.
* **Cycles:** May be administered as a single 4-day cycle or repeated every 28 days for up to 6 cycles, depending on clinical response and protocol.
## Pediatric Dosing
* **High-Dose Pulse:** 40 mg/m²/day (maximum 40 mg/day) for 4 consecutive days.
* **Alternative:** Some pediatric protocols utilize 0.6 mg/kg/day (maximum 40 mg/day) for 4 days.
* *Note: Dosing should strictly follow local institutional protocols.*
## Dose Adjustments
* **Hepatic Impairment:** Clearance may be reduced. Monitor closely for increased systemic exposure.
* **Elderly:** Use lowest effective dose; monitor for increased risk of psychiatric side effects, hyperglycemia, and bone density loss.
## Contraindications
* Systemic fungal infections.
* Known hypersensitivity to dexamethasone.
* Administration of live or live-attenuated vaccines during high-dose therapy.
## Adverse Effects
* **Common:** Hyperglycemia, insomnia, mood lability (anxiety, depression, euphoria), increased appetite, fluid retention/edema, and dyspepsia.
* **Serious:** Increased infection risk, hypertension, peptic ulcer disease, myopathy, avascular necrosis (typically with repeated cycles), and adrenal insufficiency (if abruptly discontinued after prolonged use).
## Key Drug Interactions
* **CYP3A4 Inducers (e.g., phenytoin, carbamazepine, rifampin):** May decrease dexamethasone efficacy.
* **Anticoagulants/Antiplatelets:** Increased risk of gastrointestinal bleeding.
* **NSAIDs:** Increased risk of gastric ulceration.
* **Antidiabetic Agents:** Dexamethasone may antagonize glycemic control; dose adjustments may be required.
## Monitoring
* **Platelet Counts:** Baseline and at least weekly during the peak/trough cycle.
* **Metabolic:** Blood glucose (fasting or random), blood pressure.
* **Clinical:** Signs of infection, fluid retention, and psychiatric status.
## Clinical Pearls
* **Rapid Response:** If a patient does not respond by day 7–10, additional cycles are unlikely to yield a durable response.
* **Gastroprotection:** Consider PPI or H2-receptor antagonist therapy in patients at high risk for GI ulceration.
* **Tapering:** While the 4-day pulse usually does not require a formal taper, clinical judgment should be used if the patient has received prior prolonged steroid exposure to avoid withdrawal symptoms.
* **Sleep:** Advise patients to take the dose in the morning to minimize insomnia.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Dosing protocols may vary by institution and clinical context. Always verify dosages with the most recent clinical guidelines or institutional pharmacy protocols before prescribing or administering medication.
